Atherosclerosis Imaging and the Canadian Atherosclerosis Imaging Network

详细信息    查看全文

• 作者：Jean-Claude Tardif ; MD^a ; ^{jean-claude.tardif@icm-mhi.org} ; J. David Spence ; MD^b ; Therese M. Heinonen ; DVM^c ; Alan Moody ; MD^d ; Josephine Pressacco ; MD ; PhD^a ; Richard Frayne ; PhD^e ; Philippe L'Allier ; MD^a ; Benjamin J.W. Chow ; MD^f ; Matthias Friedrich ; MD^a ; Sandra E. Black ; MD^d ; Aaron Fenster ; PhD^b ; Brian Rutt ; PhD^b ; Rob Beanlands ; MD^f
• 刊名：Canadian Journal of Cardiology
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：29
• 期：3
• 页码：297-303
• 全文大小：257 K

文摘

Atherosclerosis exacts a large toll on society in the form of cardiovascular morbidity, mortality, and resource use and is exacerbated by the epidemics of obesity and diabetes. Consequently, there is a critical need for more-effective methods of diagnosis, treatment, and prevention of the complications of atherosclerosis. Careful and well-conducted large population studies are needed in order to truly understand the natural history of the disease, its imaging biomarkers, and their links to patient outcomes. The Canadian Atherosclerosis Imaging Network (CAIN) is a unique research network funded by the Canadian Institutes of Health Research and the Canada Foundation for Innovation and designed to address these needs and to enable large population-based imaging studies. The central objective of CAIN is to move innovations in imaging toward their broad application in clinical research and clinical practice for the improved evaluation of cardiac and neurologic vascular disease. CAIN is established as an international resource for studying the natural history, progression, and regression of atherosclerosis, as well as novel therapeutic interventions aimed at atherosclerosis. The network represents Canada's leading atherosclerosis imaging experts, embodying both basic imaging science and clinical imaging research. The network is improving methods of detection and treatment of atherosclerosis and, through a better understanding of the underlying disease itself, improving strategies for disease prevention. The benefits are expected to appear in the next 2 to 3 years. CAIN will drive innovation in imaging technology within the field of cardiology and neurology and improve health outcomes in Canada and worldwide.